3,7,11,15-Tetramethyl-2,4,6,10,14,-hexadecapentaendic acid

• US 4,917,829 A
• Filed: 05/16/1986
• Issued: 04/17/1990
• Est. Priority Date: 04/07/1980
• Status: Expired due to Term

• Current Assignee: Eisai R & D Management Company Limited (Eisai Medical Research Incorporated)
• Original Assignee: Eisai Company Limited (Eisai Medical Research Incorporated)
• Inventors: Abe, Koichi, Yamada, Kouji, Suzuki, Takeshi, Abe, Shinya, Suzuki, Kouichi, Suzuki, Yoshikazu, Yamatsu, Isao, Inai, Yuichi, Tagaya, Osamu
• Primary Examiner(s): Warren, Charles F.
• Application Number:
  US06/865,934
• Time in Patent Office: 1,432 Days
• Field of Search: 260/413 C, 260/413 R, 514/560
• US Class Current: 514/560
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 8/361 Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: C07C 317/44 having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• CPC Class Codes: C07C 57/03 Monocarboxylic acids
• CPC Class Codes: C07C 69/587 Monocarboxylic acid esters having at least two carbon-to-carbon double bonds

Abstract

A novel compound, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, and a salt thereof are disclosed together with a number of different processes for the preparation of the compound. The uses of the novel compound as an anticancer agent are also disclosed.

Claims

1. 3,7,11,15-Tetramethyl-2,4,6,10,14-hexadecapentaenoic acid of the formula (I):

##STR8## or a pharmaceutically acceptable salt thereof.

2. A method of treating precancerous skin conditions which comprises administering to a subject requiring such treatment a therapeutically effective amount of a pharmaceutical composition comprising 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid of the formula (I):

##STR9## or a pharmaceutically acceptable salt theeof, and a pharmaceutical carrier.

3. A method as claimed in claim 2, in which said composition is administered orally or parenterally and the formula (I) compound is administered in a dosage of from 40 mg to 4 g, per day.